By PPN News Staff
Tixagevimab co-packaged with cilgavimab (TIX+CIL; Evusheld, AstraZeneca) may not be effective against COVID-19 variants, according to the FDA.
The agency updated the authorized Fact Sheet for TIX+CIL to include the information about an increased risk for developing COVID-19 with exposure to variants that are not neutralized by TIX+CIL.
TIX+CIL may not be as effective against the various omicron variants—especially BA. 4.6, which the CDC estimates now makes up nearly 13% of